|Systematic (IUPAC) name|
|Molar mass||291.732 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
PWZ-029 is a benzodiazepine derivative drug with nootropic effects. It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|35px||This drug article relating to the nervous system is a stub. You can help ssf by expanding it.|
- Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Research. 2008 May 7;1208:150-9. PMID 18394590